Testimonials do not necessarily represent expected patient results as determined from NeuroStar clinical trials. Before reviewing, please note the FDA-cleared indication for use and clinical trials data for NeuroStar TMS Therapy.*
Efficacy for NeuroStar TMS Therapy was established in a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapy system to an inactive device. Patients treated with active NeuroStar TMS Therapy received an average reduction in their depression symptom score of 22.1% compared to a 9% average reduction in patients receiving inactive treatment.1
Click here for full prescribing and safety information